BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures
← catalyst calendarNCT06948591 · readout ≤ 1,411 d
Sponsored by CONMED Corporation (industry) · CNMD — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-08 | actual | When the study began enrolling |
| Primary completion | Jun 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ACL Tears
Interventions
- Device: Anterior cruciate ligament reconstruction with BioBrace® augmentation
- Procedure: Arthroscopic anterior cruciate ligament reconstruction
Primary outcomes
what the primary-completion date above is the date OFImprovement in Function
measured 3 years post-op
Adverse Events
measured Baseline, 6-months, 1-, 2-, and 3-years post-op
Permalink · CNMD's whole pipeline · Catalyst calendar · Every registered study · What changed